I48 I63
Conditions
Interventions
Group 1: Duration of the amplified p-wave >137 ms or presence of advanced interatrial block (pos-neg P in two of the three inferior ECG leads)
Group 2: Duration of the amplified p-wave < 137 ms withou
Sponsors
Universitätsklinikum FreiburgCampus Bad Krozingen
Eligibility
Sex/Gender
All
Age
50 Years to 85 Years
Inclusion criteria
Inclusion criteria: - Male and female patients aged =50 years and <85 years - Digital amplified 12-Lead-ECG available in normal sinus rhythm - 12-leads ECG recorded as part of the admission examination in all patients admitted to our center will be scrutinized regarding p-wave duration - Written informed consent for study participation prior to enrollment
Exclusion criteria
Exclusion criteria: - Prior cardiac surgery - Known atrial fibrillation, atrial flutter or atrial tachycardia - Current clinical indication for oral anticoagulant therapy - Prior catheter ablation for atrial fibrillation, atrial flutter or atrial tachycardia within the right and/or left atrium - Patients with implanted cardiac devices / pacemaker / ICD - Contra-indications for cerebral MRI like e.g. claustrophobia, carriage of metal implants - Short life expectancy due to comorbid conditions - Heart failure, NYHA 4 - Severe valvular heart disease (Mitral or aortic valvulopathy >Grade 2/3) - Other major disabling disease - Acute inflammatory or infectious disease - Body mass index (BMI): =18.0 and = 36.0 kg/m² - Female patients of child-bearing potential
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| •Evaluation of the rate of clinically overt ischemic stroke/transient ischemic attack or new cerebral infarcts by MRI during the 18- and/or 36-months follow-up period in patients with vs without FAM (based on APWA) - Evaluation of Incidence of new-onset atrial fibrillation or flutter. | — |
Primary
| Measure | Time frame |
|---|---|
| The primary objective of the current pilot study is to assess the prevalence and incidence of stroke and silent cerebral infarcts by MRI at study inclusion and at 18 and 36 months FU in patients without and with electrocardiographic evidence of FAM (fibrotic atrial cardio-myopathy). | — |
Countries
Germany
Contacts
Public ContactKilian Franke
Universitätsklinikum FreiburgCampus Bad Krozingen
Outcome results
None listed